Health Care [ 12/12 ] | Pharmaceuticals [ 66/74 ]
NASDAQ | Common Stock
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program.
Scilex Holding Company is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 24 | -0.25 Decreased by -92.31% | -0.23 Decreased by -8.70% |
| Nov 13, 23 | -0.63 Decreased by -6.20 K% | -0.17 Decreased by -270.59% |
| Aug 30, 23 | -0.19 Decreased by -255.67% | - |
| May 12, 23 | -0.22 Decreased by -340.00% | - |
| Mar 7, 23 | -0.13 Decreased by -285.71% | - |
| Nov 4, 22 | -0.01 Increased by +87.50% | - |
| Aug 12, 22 | 0.12 Increased by +50.00% | - |
| May 16, 22 | -0.05 Decreased by -164.94% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 10.12 M Decreased by -11.07% | -35.53 M Decreased by -265.24% | Decreased by -351.18% Decreased by -285.82% |
| Jun 30, 23 | 12.58 M Increased by +58.74% | -26.65 M Decreased by -49.39% | Decreased by -211.80% Increased by +5.89% |
| Mar 31, 23 | 10.58 M Increased by +55.34% | -30.75 M Decreased by -236.36% | Decreased by -290.62% Decreased by -116.52% |
| Dec 31, 22 | 11.92 M Increased by +52.24% | -17.88 M Increased by +19.10% | Decreased by -150.05% Increased by +46.86% |
| Sep 30, 22 | 11.38 M Increased by +45.31% | 21.50 M Increased by +197.26% | Increased by +188.99% Increased by +166.93% |
| Jun 30, 22 | 7.93 M Increased by +1.24% | -17.84 M Increased by +19.31% | Decreased by -225.06% Increased by +20.29% |
| Mar 31, 22 | 6.81 M Decreased by -12.99% | -9.14 M Increased by +58.64% | Decreased by -134.22% Increased by +52.46% |
| Dec 31, 21 | 7.83 M Increased by +32.92% | -22.11 M Decreased by -86.08% | Decreased by -282.35% Decreased by -39.99% |